key: cord-0919683-fdih8f9q
authors: Fabre, Olivier; Rebet, Olivier; Carjaliu, Ionut; Radutoiu, Mihai; Gautier, Laurence; Hysi, Ilir
title: Severe Acute Proximal Pulmonary Embolism and COVID-19: A Word of Caution
date: 2020-04-17
journal: Ann Thorac Surg
DOI: 10.1016/j.athoracsur.2020.04.005
sha: 7eacc87732e1b37ccce76b9cb8fe3fd46bf63521
doc_id: 919683
cord_uid: fdih8f9q

Abstract Acute pulmonary embolism is an uncharacteristic presentation in patients with COVID-19. Here we describe the case of a young woman presenting with severe pulmonary embolism, without any associated symptoms of infections. A clot in a patent foramen ovale was noted. Despite emergency surgical embolectomy, her clinical conditions continued to deteriorate. She was put on extracorporeal life support and tested positive for COVID-19. She died of multiorgan failure on day 10. COVID-19 may have a thrombogenic effect and it may need to be considered in cases of pulmonary embolism and in absence of any obvious risk factor.

The recent COVID-19 pandemic is placing practitioners under the pressure to cope with novel challenges it presents, in terms of clinical identification of the different symptoms of the pathology and testing of new or already known treatments (1, 2) .

Much attention is dedicated to the potential COVID-19 has to cause ALI/ARDS, but cases of acute pulmonary embolism in COVID-19 patients are also very recently described. Coincident pulmonary embolism has been detected on CT-scans of patients hospitalized mainly for infectious respiratory symptoms (3, 4) . Here we discuss the clinical case of a patient presenting with severe proximal pulmonary embolism, in absence of pneumonia, and who was tested positive for COVID-19 nine days after her admission.

A 45-year-old female patient was admitted to our emergency department, in the north of France. She had an active lifestyle, but had a body mass index of 40.4 kg/m², and was under any-hypertensive therapy (Ramipril 5 mg per day). She was not receiving oral contraceptives.

The patient complained of dyspnea and sore throat, without any associated fever or coughs for one week prior to admission to hospital and had taken Ibuprofen as self-medication. On

March 18 th 2020, the day of her admission, she developed brutal chest pain, syncope and tachypnea. Arterial blood gas measurements revealed a pO2 of 54 mmHg and pCO2 A post hoc analysis of the initial CT-scan, made by the radiologists, found already the presence of slight bilateral interstitial ground-glass opacities compatible with COVID-19 lung parenchymal lesions (Figure 3ab ).

COVID-19 related pathology has been constantly evolving during the last month. To the best of our knowledge, association between acute pulmonary embolism and COVID-19 has been reported only in two very recent publications (3, 4) . Unlike our patient, whose clinical presentation was dominated by the acute embolism, with no fever, cough and muscular fatigue, in these publications pulmonary embolisms were diagnosed retrospectively on the CT-scan of the patients presenting with COVID-19 "classic" infectious respiratory clinical affections. Our patient was not identified as a potential COVID-19 patient and was not tested because her strong chest pain, syncope and tachypnea were attributed to the acute proximal pulmonary embolism and except for the dyspnea and the sore throat, she didn't have the "classic" symptoms usually associated with COVID-19.

The probability of a nosocomial COVID-19 infection, during our patient's hospital stay is minimal, since she remained intubated in sterile conditions in the intensive care unit with no member of the attending team testing positive or developing any COVID-19 signs over this period of time. Additionally, a post hoc analysis of the initial CT-scan already showed signs consistent with COVID-19 lung lesions.

It is difficult to take a definite position on the role of treatment our patient received prior to her admission to the hospital. Angiotensin-converting enzyme 2 (ACE2) is a co-receptor for viral entry for SARS-CoV-2 and it may have a role in COVID-19 pathogenesis, although there is insufficient evidence to link ACE inhibitors or Renine-Angiotensine system blockers to severe forms of COVID-19 (5, 6) . A similar uncertainty exists as to the role of the patient's Ibuprofen oral intake, and its potential relationship with severe forms of COVID-19 (7) .

Although the evidence is insufficient to establish a firm association between pulmonary embolism and COVID-19, the latter may have a thrombogenic effect and eventually cause 6 pulmonary embolism. Cases of pulmonary embolism were also noted during the coronavirus severe acute respiratory syndrome (SARS) epidemic in 2003. Indeed, an underlying thrombophilic state, with frequent pulmonary embolisms in necropsy series of SARS patients, was reported (8) .

In conclusion, we wanted to raise awareness of the potential that COVID-19 and severe acute pulmonary embolism may be related and. in absence of clear symptoms currently associated with this viral infection, the clinic may be totally dominated by the hemodynamic or respiratory symptoms of acute pulmonary embolism. For this reason, when presented to a patient with pulmonary embolism, without any evident risk factor for this pathology, the potential association between COVID-19 and pulmonary embolism should also be considered.

If true, the early detection of COVID-19 infections can lead to a prompter and more aggressive systemic treatment, according to local recommendations or in-evaluation protocols. 

Covid-19 in Critically Ill Patients in the Seattle Region -Case Series

Controversial treatments: an updated understanding of the Coronavirus Disease

Acute pulmonary embolism and COVID-19 pneumonia: a random association?

COVID-19 Complicated by Acute Pulmonary Embolism

Renin-Angiotensin System Blockers and the COVID-19 Pandemic: At Present There Is No Evidence to Abandon Renin-Angiotensin System Blockers

Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19

Covid-19: ibuprofen should not be used for managing symptoms, say doctors and scientists

Pulmonary artery thrombosis in a patient with severe acute respiratory syndrome